3 citations
,
July 2025 in “Obesity Facts” This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.
1 citations
,
September 2025 in “Dermatology and Therapy” This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.
July 2026 in “Journal of the American Academy of Dermatology” GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.
August 2026 in “Dermatology and Therapy” In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.
August 2026 in “Journal of Cosmetic Dermatology” This study observed that dermatological and hair changes, like skin sagging and hair shedding, commonly occur early during weight loss with GLP-1 receptor agonists, highlighting the need for tailored dermatological care alongside treatment.